№2_2022

ПОВОЛЖСКИЙ
ОНКОЛОГИЧЕСКИЙ
ВЕСТНИК Том 13, №2. 2022
— 94. — P. 115-125. doi: 10.1016/j.
ejca.2018.02.012. Epub 2018 Mar 20.
Erratum in: Eur J Cancer. 2018 Nov;103:287.
PMID: 29550566; PMCID: PMC6057479.
25. Choueiri T.K., Escudier B., Powles T. et al.
Cabozantinib versus everolimus in advanced
renal cell carcinoma (METEOR): Final results from
a randomised, open-label, phase 3 trial // Lancet
Oncol. — 2016. — 17. — P. 917-927.
26. Matsuki M., Adachi Y., Ozawa Y. et al. Targeting
of tumor growth and angiogenesis underlies
the enhanced antitumor activity of lenvatinib in
combination with everolimus // Cancer Sci. —
2017. — 108. — P. 763-771.
27. Escudier B.J., Powles T., Motzer R.J. et al.
Efficacy of cabozantinib (C) vs everolimus
(E) in patients (pts) with advanced renal cell
carcinoma (RCC) and bone metastases (mets)
from the phase III METEOR study. Abstract
(4558) and poster (180) presented at the
Annual Meeting of the American Society of
Clinical Oncology; June 3–7, 2016; Chicago, IL.
28. Cella D., Escudier B., Powles T.B. et al. Quality
of life (QoL) in the phase 3 METEOR trial of
cabozantinib vs everolimus for advanced renal
cell carcinoma (RCC). Abstract and poster
(816P) presented at the Annual Congress of the
European Society for Medical Oncology; October
7–11, 2016; Copenhagen, Denmark.
29. Heng D.Y., Xie W., Regan M.M., et al. Prognostic
factors for overall survival in patients with
metastatic renal cell carcinoma treated with
vascular endothelial growth factor-targeted
agents: results from a large, multicenter study //
J. Clin. Oncol. — 2009. — 27. — P. 5794-9.
30. Heng D.Y.C., Xie W., Regan M.M., et al. External
validation and comparison with other models
of the International Metastatic Renal-Cell
Carcinoma Database Consortium prognostic
model: a populationbased study // Lancet Oncol.
— 2013. — 14. — P. 141-8.
31. Choueiri T.K., Powles T., Burotto M., et al.;
CheckMate 9ER Investigators. Nivolumab
plus Cabozantinib versus Sunitinib
for Advanced Renal-Cell Carcinoma //
N. Engl. J. Med. — 2021, Mar 4. — 384 (9). —
P. 829-841. doi: 10.1056/NEJMoa2026982.
PMID: 33657295; PMCID: PMC8436591.
32. Rini B.I., Plimack E.R., Stus V., et al.
Pembrolizumab plus axitinib versus sunitinib
for advanced renal-cell carcinoma //
N. Engl. J. Med. — 2019. — 380. — P. 1116-27.
33. Motzer R.J., Penkov K., Haanen J., et al.
Avelumab plus axitinib versus sunitinib
for advanced renal-cell carcinoma //
N. Engl. J. Med. — 2019. — 380. — P. 1103-15.
34. Motzer R.J., Tannir N.M., McDermott D.F.,
et al. Nivolumab plus ipilimumab versus
sunitinib in advanced renal-cell carcinoma //
N. Engl. J. Med. — 2018. — 378. — P. 1277-90.
35. Grimm M.O., Leucht K., Grünwald V., et al. New
first line treatment options of clear cell renal cell
cancer patients with PD-1 or PD-L1 immunecheckpoint
inhibitor-based combination
therapies // J. Clin. Med. — 2020. — 9. — 565.
36. Злокачественные новообразования в России
в 2020 году (заболеваемость и смертность)
/ Под ред. А.Д. Каприна, В.В. Старинского,
А.О. Шахзадовой. — М.: МНИОИ им.
П.А. Герцена — филиал ФГБУ «НМИЦ радиологии»
Минздрава России, 2021. — 252 с.
37. Ганцев Ш.Х., Меньшиков К.В. Онкологическая
служба в условиях пандемии COVID-19 (обзор
литературы) // Креативная хирургия и
онкология. — 2020. — 10 (3). — C. 233-240.
https://doi.org/10.24060/2076-3093-202010-3-
233-240.
38. Hanna N., Sun M., Meyer C.P., et al. Survival
analyses of patients with metastatic renal
cancer treated with targeted therapy with
or without cytoreductive nephrectomy: a
national cancer data base study // J. Clin.
Oncol. — 2016. — 34 (27). — P. 3267e75.
39. Manola J., Royston P., Elson P., et al. Prognostic
model for survival in patients with metastatic
renal cell carcinoma: results from the
international kidney cancer working group //
Clin. Cancer Res. — 2011. — 17 (16). — P. 5443e50.
20 Клинические исследования и опыт в онкологии